Active	Status	Sponsor type	Region	Phase	Filter
13 Active 11 Inactive 24 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Kevin
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs	Recruiting	3	400	US	Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy	Replimune Inc.	Advanced Melanoma	01/29	08/34
CPMC17-MEL01, NCT03925350: Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	Recruiting	2	41	US	Niraparib	California Pacific Medical Center Research Institute, Tesaro, Inc., Vanderbilt-Ingram Cancer Center, Huntsman Cancer Institute	Metastatic Melanoma	02/22	02/23
NCT04633902: Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	Recruiting	2	41	US	Olaparib, Lynparza, Pembrolizumab, Keytruda	California Pacific Medical Center Research Institute, M.D. Anderson Cancer Center	Metastatic Melanoma	06/23	12/24
NCT05077280: A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma	Recruiting	2	40	US	stereotactic body radiotherapy, Immunotherapy	California Pacific Medical Center Research Institute	Uveal Melanoma	03/24	03/26
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis	Recruiting	2	288	US	CIN-102 Dose 15mg or 10mg, Placebo	CinDome Pharma, Inc.	Diabetic Gastroparesis	09/25	09/25
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers	Active, not recruiting	2	77	Europe, Canada, US	SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin	Seagen Inc., Merck Sharp & Dohme LLC	Melanoma, Carcinoma, Non-Small- Cell Lung	01/24	10/25
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Recruiting	2	30	US	RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Replimune Inc., Roche Pharma AG	Hepatocellular Carcinoma	12/27	07/28
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma	Recruiting	2	267	US, RoW	mRNA-4157, Pembrolizumab	ModernaTX, Inc., Merck Sharp & Dohme LLC	Melanoma	09/29	09/29
NCT00600496: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) P1 data Mar 2012 - Mar 2012: P1 data	Active, not recruiting	1	140	US	AZD6244, ARRY-142886, Dacarbazine, Erlotinib, Docetaxel, Taxotere®, Temsirolimus	AstraZeneca	Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer	08/10	12/24
NCT04601428: Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)	Recruiting	1	43	RoW	IA therapy of HCC with CSR02-Fab-TF	Koo Foundation Sun Yat-Sen Cancer Center	Hepatocellular Carcinoma (HCC)	12/24	12/24
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours	Active, not recruiting	1	123	Europe, US	RP3, Nivolumab	Replimune Inc., Bristol-Myers Squibb	Advanced Solid Tumor	11/26	11/26
NCT05740293: Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment with the VisuMax SMILE Procedure	Active, not recruiting	N/A	171	US	VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism	Carl Zeiss Meditec, Inc.	Myopia, Astigmatism	09/24	03/25
Margolis, Eric
TITAN 2, NCT05226286: Evaluation of Implantable Tibial Neuromodulation Pivotal Study	Active, not recruiting	N/A	188	US	Medtronic Implantable Tibial Neuromodulation (TNM) System	MedtronicNeuro	Overactive Bladder	10/23	04/25
Blizzard, Michael
No trials found